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Abstract
Background: The incidence of tuberculosis (TB) is high among human immunodeficiency virus (HIV) infected
Ugandans. Recent evidence suggests that Chronic Pulmonary Aspergillosis and Aspergillus sensitisation might be
responsible for significant mortality in patients treated for tuberculosis in Uganda.
Methods: We retrieved and tested paired serum aliquots for 101 HIV-TB co-infected patients at the beginning and week
24 of TB treatment. We tested samples for Aspergillus-specific immunoglobulin G (IgG) and immunoglobulin E (IgE) using
ImmunoCAP®; and Aspergillus-specific IgG and total serum IgE using Immulite® immunoassays. We compared antibody
levels between baseline and week 24, relating them to selected baseline characteristics.
Results: 10% of the patients had elevated Aspergillus-specific IgE (Aspergillus sensitization) and Aspergillus-specific IgG
antibodies were elevated in 9% of the patients at the end of TB treatment. There was a significant fall in the Aspergillus-
specific IgG antibody levels between baseline and week 24 (P = 0.02). Patients with cluster of differentiation 4 (CD4) T-cell
count <100 cells/μl and those who were not on anti-retroviral therapy at baseline had more elevated Aspergillus-specific
IgG antibodies (P = 0.01, P = 0.03). The ImmunoCAP® Aspergillus-specific IgG antibody titres were higher at week 24 than
baseline with more positives at week 24; even though the difference in means was small. However, this difference was
statistically significant (P = 0.02). Pulmonary infiltrates were the commonest x-ray abnormality and only 5% of the patients
had pulmonary cavities on chest x-ray at week 24.
Conclusion: These results suggest that Aspergillus infection may complicate active pulmonary TB and further studies
including fungal culture and thoracic imaging may now be indicated to measure the prevalence of pulmonary
aspergillosis complicating tuberculosis.
Trial registration: The SOUTH trial was registered prospectively. ClinicalTrials.gov Identifier: NCT01782950; Registration
date: 4th February 2013; Last verified: 13th April 2015.
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Background
Tuberculosis (TB) remains one of the major causes of mor-
bidity and mortality worldwide with the highest burden
found in Africa and Asia, mainly linked to the human im-
munodeficiency virus (HIV) epidemic [1]. The 2016 World
Health Organization (WHO) report on TB revealed that
there were an estimated 10 million new cases of TB in the
year 2015 worldwide, with 11% having HIV. An estimated
1.8 million people died due to TB in 2015, including 0.4
million deaths due to HIV/TB co-infection. The incidence
of TB among HIV patients in Uganda was estimated at 202
new cases per 100,000 population [2].
Due to the limited published data on fungal disease
epidemiology in sub-Saharan Africa, a recent review
attempted to estimate the burden of fungal infections in
Uganda using specific populations [3]. In this review,
chronic pulmonary aspergillosis (CPA) was estimated at
12–22% in TB patients with cavities and 1–4% in those
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without cavities. Considering post-TB data in Uganda,
asymptomatic CPA was estimated at 7% with an additional
1.7% having detectable Aspergillus-specific immunoglobulin
G (IgG) antibodies with cavitation.
Recent work done in Northern Uganda has validated
some of these estimates, with a CPA prevalence of 8.2%,
and 6.7% having cavities among patients who had been
successfully treated for pulmonary TB within the last 7 years
[4, 5]. More results from this work showed Aspergillus-spe-
cific IgG antibody levels were raised in 26% of patients with
“smear negative TB” and suggested that previously
unrecognized CPA might be responsible for significant
mortality in patients treated for TB in Uganda [6–8].
Beyond this limited data, little is known about the epidemi-
ology of fungal colonisation and sensitisation, and their
contribution to TB disease progress and treatment
outcomes in Uganda where pulmonary TB is very common,
in part driven by the high prevalence of HIV [9].
We hypothesized that patients with pulmonary TB
may get colonized with Aspergillus during and in the
post treatment period leading to a chronic lung infection
and/or allergic fungal disease if the patient was pre-
sensitized to Aspergillus antigens. Pulmonary cavitation
is a pre-disposing factor for CPA [10] and may or may
not present together with Aspergillus sensitization. We
therefore aimed to establish and compare Aspergillus-
specific antibody levels among HIV-infected Ugandans
with TB, at the beginning and end of TB treatment;
using ImmunoCAP® and Immulite® immunoassays.
Methods
Study design and population
This was a nested cohort study under the “Study on
Outcomes related to Tuberculosis and HIV drug con-
centrations in Uganda” (SOUTH) (ClinicalTrials.gov:
NCT01782950). SOUTH was a prospective study in-
vestigating the correlation of anti-tuberculosis drug
concentrations and TB treatment outcomes in HIV-
infected individuals with pulmonary TB at the Infec-
tious Diseases Institute, Kampala, Uganda [11]. All
participants were HIV-TB co-infected patients above
18 years with a diagnosis of their first episode of pul-
monary TB i.e. proven or highly suspected TB consid-
ered for TB treatment qualifying for 6 months
(24 weeks) anti-TB drugs regimen (2 months HRZE
[isoniazid (H), rifampicin (R), pyrazinamide (Z) and
ethambutol (E)] and 4 months HR [isoniazid (H) and
rifampicin (R)]). Patients with multi-drug resistant TB
were excluded. Only 32% of the participants already
had an HIV diagnosis with an average time since
diagnosis of 53 days. The rest of the participants were
diagnosed at TB screening. Each participant was
followed up for 24 weeks.
Study samples
Samples used for this study were stored serum samples
from the SOUTH study population (stored at −80°c). We
cross checked the sample storage inventories to look out
for participants that had a sample stored at beginning
(baseline) and end of TB treatment (week 24). We included
all patients with two aliquots i.e. one at baseline and one at
week 24. Samples were then shipped and tested at the
Mycology Reference Centre Manchester and Christie
Hospital, Manchester, United Kingdom (UK).
Study assays
Testing was initially done using the ImmunoCAP® ma-
chine (ThermoFisher®, previously Phadia) to check for
levels of Aspergillus-specific IgG (Asp IgG) at baseline
and week 24. Also, using ImmunoCAP Aspergillus-spe-
cific IgE (Asp IgE) antibody levels were checked at week
24 only. Further testing for total serum IgE (TIgE) levels
at both baseline and week 24 was undertaken on the
Immulite 2000® machine (Siemens). Remaining serum
was re-tested for Aspergillus-specific IgG levels using the
Immulite machine (Additional file 1).
Assay cut-offs
We used a cut-off of 40 mg/l for the ImmunoCAP
Aspergillus-specific IgG levels as recommended by
manufacturer, and a cut-off of 20 mg/l for the Immulite
Aspergillus-specific IgG levels based on preliminary re-
sults of a cross-sectional survey in Uganda [4]. Varia-
tions in the cut-off for total serum IgE have been
reported ranging from 150 to 1000 UI/ml [12]. However,
a cut-off of 1000 UI/ml is recommended for diagnosis of
allergic bronchopulmonary aspergillosis (ABPA) [13].
Therefore, for our study, we used a cut-off of 170 UI/ml
to check for general allergy and a cut-off of 1000 UI/ml
as a screen for evidence of ABPA. A cut-off of 0.35 kU/l
was used for Aspergillus-specific IgE levels as recom-
mended by the manufacturer.
Data analysis
Data were analyzed using STATA® version 13 (STATA,
College Station, Texas). Our primary data analysis
aimed at comparing the Aspergillus-specific IgG anti-
body levels at baseline compared with week 24, and
relating them to baseline demographics and clinical pa-
rameters (Additional file 1) at a 95% confidence
interval.
Results
Study population characteristics
Of 268 patients in the SOUTH study, we selected all
participants (n = 101) with a pre and post treatment
serum sample; that were enrolled into the SOUTH study
between March 2013 and July 2014. Of participants, 56%
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(56/101) were men and the median age of all participants
at TB diagnosis was 33 years (interquartile range (IQR),
27–38). All participants were HIV-infected adults with a
median baseline CD4 T cell count of 155 cells/μl (IQR,
31–269, n = 98). Only 31% (31/101) of the participants
were receiving anti-retroviral therapy (ART) at TB diagno-
sis. At baseline, 41% (41/101) had chest pain, 27% (27/
101) had difficulty in breathing, 94% (95/101) had a cough
and 89% (90/101) had sputum production with a median
cough duration of 4 weeks (IQR, 3–12, n = 95) (Table 1).
TB was diagnosed by direct microscopy (smear),
genexpert-MTB/RIF®, Mycobacteria growth indicator tube
(MGIT) and Löwenstein–Jensen (LJ) culture. Only 47%
(46/97) of the participants had positive sputum smears at
TB diagnosis and 73% (24/33) had positive sputum genex-
pert MTB/RIF results. 68% (64/94) of the participants had
positive MGIT while 60% (55/92) had positive LJ cultures.
For participants who had chest x-rays done at baseline,
91% (80/88) had abnormal x-rays. The commonest chest
x-ray abnormalities registered were pulmonary infiltrates
(91% [73/80]) followed by pleural effusion (19% [15/80])
and cavities (6% [5/80]) (Table 1).
Aspergillus-specific IgG antibody levels using
ImmunoCAP®
Using the ImmunoCAP immunoassay, the baseline me-
dian Aspergillus-specific IgG antibody levels were 4.43 mg/
l (IQR, 2.07–7.17) with 4% (3/76) of the patients having el-
evated levels (>40 mg/l); while at week 24, the median As-
pergillus-specific IgG antibody levels were 4.9 mg/l (IQR,
2.13–9.14) with 2% (2/94) having elevated levels (Table 2).
All three patients who were positive for Aspergillus-spe-
cific IgG at baseline had become sero-negative by week 24
without antifungal treatment. Their x-rays had also im-
proved with a normal picture at week 24.
Seven patients were negative for all the TB diagnostics
(i.e. smear, genexpert, MGIT, LJ) but with abnormal chest
x-rays. For these patients, a presumptive diagnosis of TB
was made based on the abnormal chest x-ray. However,
on comparing the baseline and week 24 x-rays, they all
showed marked improvement, but only two had normal
week 24 x-rays. These seven patients had Aspergillus–spe-
cific IgG antibodies in the range of <2 to 7.22 mg/l at
baseline and <2 to 21.8 mg/l at week 24. The higher titers
at week 24 than baseline could suggest that there is an
Table 1 Characteristics of the study population at TB diagnosis
Descriptions N Statistics
Baseline Demographics
Males, n (%) 101 56 (56)
Age at TB diagnosis, mean
(SD)/ median (IQR)
101 34 (8)/ 33 (27, 38)
On ART at TB diagnosis, n (%) 101 31 (31)
CD4 (cells/μL) at TB diagnosis,
median (IQR)a
98 155 (31, 269)
Respiratory symptoms at TB diagnosis
Cough, n (%) 101 95 (94)
Cough duration in weeks,
median (IQR)a
95 4 (3, 12)
Chest pain, n (%) 101 41 (41)
Difficulty in breathing, n (%) 101 27 (27)
TB diagnostics
Positive Sputum smear, n (%)a 97 46 (47)
Abnormal Chest X-ray, n (%)a 88 80 (91)
Pulmonary Infiltrates on chest
x-ray, n (%)a
80 73 (91)
Pleural Effusion on chest
x-ray, n (%)a
80 15 (19)
Cavities on chest x-ray, n (%)a 80 5 (6)
Positive Genexpert, n (%)a 33 24 (73)
Positive MGIT, n(%)a 94 64 (68)
Positive LJ culture, n(%)a 92 55 (60)
Data presented are percentages (%), standard deviations (SD) and interquartile ranges (IQR)
EH ethambutol and Isoniazid, RH rifampicin and Isoniazid, MGIT Mycobacteria growth indicator tube, LJ Löwenstein–Jensen
aSome parameters have N < 101 due to missing data
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Table 2 Summary of Aspergillus-specific antibody titers and total serum IgE in HIV/TB patients in relation to selected baseline
characteristics
Test/ Assay/ Cut-off Factor at TB diagnosis BASELINE WEEK 24 Overall
P value$N Median (IQR) P value* N Median (IQR) P value*
Aspergillus IgG
ImmunoCAP®
cut-off = 40 mg/L
Overall 76 4.4 (2.1,7.2) NA 94 4.9 (2.1, 9.1) NA 0.02
Not on ART 52 4.3 (2.1,7.3) 0.85 65 4.9 (2.7,10.4) 0.35
On ART 24 4.8 (2.0,6.9) 28 2.8 (2.0,7.5)
CD4 < 100/μL 26 6.2 (2.7,8.7) 0.01 31 5.3 (2.1,12.7) 0.47
CD4≥ 100/μL 47 3.2 (2.0,6.0) 59 4.8 (2.1,7.5)
Coughed for
<3 weeks
27 5.2 (2.1,8.5) 0.50 29 4.9 (2.3,10.4) 0.96
Coughed for
≥3 weeks
49 4.3 (2.0,7.1) 64 4.9 (2.1,9.0)
No Chest pain 41 5.4 (2.7,8.2) 0.03 55 4.8 (2.1,8.8) 0.95
Chest pain 35 2.9 (2.0,6.2) 38 5.1 (2.4,10.1)
Abnormal Chest
X-Ray
59 4.3 (2.0,7.1) 0.79 75 4.9 (2.1,8.8) 0.88
Normal Chest
X-Ray
6 3.9 (2.6,8.7) 6 3.1 (2.1,10.9)
Aspergillus IgG
Immulite®
cut-off = 20 mg/L
Overall 75 7.5 (6.1, 10.3) NA 87 7.2 (6.1, 9.96) NA 0.66
Not on ART 52 8.0 (6.7,10.6) 0.03 61 7.6 (6.2,10.5) 0.27
On ART 23 6.6 (5.8,8.2) 26 6.9 (6.1,8.8)
CD4 < 100/μL 25 7.9 (5.9,9.1) 0.94 29 7.8 (6.0,11.3) 0.60
CD4≥ 100/μL 47 7.5 (6.1,10.4) 56 7.0 (6.1,9.5)
Coughed for
<3 weeks
26 7.3 (6.0,8.8) 0.37 28 7.6 (5.9,10.5) 0.98
Coughed for
≥3 weeks
49 7.5 (6.4,10.7) 59 7.2 (6.2,8.8)
No Chest pain 40 7.5 (6.4,10.8) 0.54 51 7.5 (6.1,9.7) 0.92
Chest pain 35 7.9 (6.0,9,3) 36 7.2 (6.1,10.8)
Abnormal Chest
X-Ray
58 7.5 (6.1,9.1) 0.30 69 7.0 (6.1,10.1) 0.80
Normal Chest
X-Ray
6 6.8 (5.0,8.2) 6 8.2 (7.5,8.7)
Total IgE
Immulite®
cut-off = 1000 IU/mL
Overall 76 379 (129, 908) NA 85 251 (64, 794) NA <0.01
Not on ART 52 371 (122,1059) 0.82 59 297 (55,1021) 0.53
On ART 24 382 (175,837) 26 231 (77,777)
CD4 < 100/μL 26 462 (149,1440) 0.11 29 595 (113,1272) 0.03
CD4≥ 100/μL 47 355 (114,634) 54 185 (57,532)
Coughed for
<3 weeks
27 207 (48,489) 0.02 26 213 (39,821) 0.49
Coughed for
≥3 weeks
49 493 (172,1200) 59 359 (71,794)
No Chest pain 41 355 (149,605) 0.40 49 183 (55,570) 0.06
Chest pain 35 489 (121,1221) 36 460 (72,1192)
Abnormal Chest
X-Ray
59 457 (149,1055) 0.53 68 332 (66,835) 0.54
Normal Chest
X-Ray
6 401 (322,1487) 6 153 (73,292)
NORMAL (≤0.35), n(%) HIGH (>0.35), n(%) P-VALUE
Aspergillus IgE Overall, N = 93 NOT APPLICABLE 84 (90.3) 9 (9.7)
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increase in the aspergillus colonization due to the increasing
pulmonary abnormalities especially cavities caused by TB.
However, for these seven patients, both titers were below the
diagnostic cut-off and not significantly different (P > 0.05).
There was a significant difference in the Aspergillus-
specific IgG antibody levels between baseline and week
24 (P = 0.02) (Fig 1a). Patients with a baseline CD4 T-
cell count <100 cells/μl had significantly higher median
baseline Aspergillus-specific IgG titers (n = 26, median =
6.2 mg/l, IQR = 2.7 to 8.7) than those with a baseline
CD4 T-cell count of ≥100 cells/μl (n = 47, median =
3.2 mg/l, IQR = 2.0 to 6.0) (P = 0.01). Patients with chest
Table 2 Summary of Aspergillus-specific antibody titers and total serum IgE in HIV/TB patients in relation to selected baseline
characteristics (Continued)
Test/ Assay/ Cut-off Factor at TB diagnosis BASELINE WEEK 24 Overall
P value$N Median (IQR) P value* N Median (IQR) P value*
ImmunoCAP®
cut-off = 0.35 kU/L
Not on ART 59(90.8) 6(9.2) 0.99
On ART 25(89.3) 3(10.7)
CD4 < 100/μL 26 (83.9) 5 (16.1) 0.26
CD4≥ 100/μL 56 (93.3) 4 (6.7)
Coughed for
<3 weeks
25(86.2) 4(13.8) 0.45
Coughed for
≥3 weeks
59(92.2) 5(7.8)
No Chest pain 51(92.7) 4(7.3) 0.48
Chest pain 33(86.8) 5(13.2)
Abnormal Chest
X-Ray
67(89.3) 8(10.7) 0.99
Normal Chest
X-Ray
6(100.0) 0 (0.0)
Data presented are diagnostic cut-offs, antibody median (interquartile ranges) and P-values comparing antibody titers between selected parameters, baseline and
end of TB treatment (wk24)
NA not applicable
*P-values were obtained using Kruskal-Wallis equality-of-populations rank test. $ P-values were obtained using Wilcoxon matched-pairs sign-rank test because of
skewed data
a b
c d
Fig. 1 Scatter plots of antibody levels at baseline and week 24. a Shows a significant difference in Aspergillus-specific IgG levels between baseline
and week 24 using ImmunoCAP. b Shows no significant difference in Aspergillus-specific IgG levels between baseline and week 24 using
Immulite. c Shows a significant difference in total serum IgE levels between baseline and week 24 using Immulite. d Shows distribution of
Aspergillus-specific IgE levels at week 24
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pain at baseline had significantly lower median Aspergil-
lus-specific IgG titers (n = 35, median = 2.9 mg/l, IQR =
2.0 to 6.2) than those without chest pain (n = 41, median
= 5.4 mg/l, IQR = 2.7 to 8.2) (P = 0.03) (Table 2). Chest
pain is not a specific symptom. Out of the 41/101
patients who had chest pain, only one had elevated IgG
levels. Out of the 60/101 patients without chest pain,
only two had elevated IgG levels. The observed outcome
could be explained by other factors related to TB but
not CPA.
Aspergillus-specific IgG antibody levels using Immulite
2000®
Using the Immulite immunoassay, the median Aspergillus-
specific IgG antibody levels were 7.52 mg/l (IQR, 6.08–
10.3) with 4% (3/75) of the patients having elevated titers
at baseline; while at end of week 24, the median Aspergil-
lus-specific IgG antibody levels were 7.21 mg/l (IQR,
6.08–9.96) with 9.2% (8/87) having elevated levels (Table 2).
Only three patients (different from the 3 in ImmunoCAP)
were positive at baseline and two of them remained posi-
tive at week 24, but with lower antibody titers. Seven
patients were negative for all the TB diagnostics (i.e. smear,
genexpert, MGIT, LJ) but with abnormal chest x-rays.
These seven patients had aspergillus IgG antibodies in the
range of 4.26 to 8.23 mg/l at baseline and 4.31 to 14.9 mg/
l at week 24.
There was no significant difference in the Aspergillus-
specific IgG antibody levels between baseline and week 24
(p = 0.66) (Fig 1b). Patients who were not on antiretroviral
therapy at TB diagnosis had significantly higher median
Aspergillus-specific IgG titers (n = 52, median = 8.0 mg/l,
IQR = 6.7 to 10.6) than those who were already taking
antiretroviral therapy at TB diagnosis (n = 23, median =
6.6 mg/l, IQR = 5.8 to 8.2) (P = 0.03) (Table 2).
Total serum IgE using Immulite 2000®
Total serum IgE was measured using Immulite assay
with a cut-off of 170 IU/ml. The median total serum IgE
levels were 379 IU/ml (IQR, 129–908) with 71% (54/76)
of the patients having elevated titers at baseline; while at
week 24, the median total serum IgE levels were 251 IU/
ml (IQR, 64–794) with 58% (49/85) of patients having
elevated levels (Table 2). We then analyzed results using
a cut-off to 1000 IU/ml. Only 24% (18/76) of the pa-
tients had total serum IgE greater than 1000 IU/mL at
baseline and 21% (18/85) at week 24. There was a sig-
nificant difference in the total serum IgE antibody levels
between baseline and week 24 (p < 0.01) (Fig 1c).
Patients who had coughed for more than three weeks
at TB diagnosis had significantly higher median total
serum IgE titers (n = 49, median = 493 IU/ml, IQR = 172
to 1200) than those who had coughed for less than three
weeks at TB diagnosis (n = 27, median = 207 IU/ml, IQR
= 48 to 489) (P = 0.02). Patients with a CD4 T-cell count
<100 cells/μl at week 24, had significantly higher median
total serum IgE titers (n = 29, median = 595 IU/ml, IQR
= 113 to 1272) than those with a baseline CD4 T-cell
count of ≥100 cells/μl (n = 54, median = 185 IU/ml, IQR
= 57 to 532) (P = 0.03) (Table 2).
Aspergillus-specific IgE antibody levels using
ImmunoCAP®
Aspergillus-specific IgE antibody levels were measured at
end of TB treatment only (Fig 1d), and were elevated in
9.7% (9/93) of the patients using a diagnostic cut-off of
<0.35kU/l (Table 2). There was no significant relationship
between Aspergillus sensitization (Asp IgE) and baseline
characteristics or respiratory symptoms.
Discussion
The study demonstrated that Aspergillus-specific IgG anti-
bodies were elevated in 4% of HIV-infected Ugandan
adults at the start of TB treatment and in 9% at the end of
TB treatment. Using ImmunoCAP, participants with CD4
T-cell counts <100 cell/μl had more elevated Aspergillus-
specific IgG antibodies (P = 0.01). The increased level of
immunosuppression could have increased their suscepti-
bility to the opportunistic fungal infection. Hyper IgG
levels are common in acquired immune deficiency syn-
drome (AIDS) patients and represent an unrestrained B-
cell response in the absence of T-cells [14]. The Immuno-
CAP Aspergillus-specific IgG antibody titers were higher
with more positives at end of TB treatment than baseline,
even though the difference in means was small. However,
this difference was statistically significant (P = 0.02). Initi-
ation of antiretroviral therapy and anti-TB medication
could have improved the patients’ ability to mount a good
immune response at week 24 than baseline.
Patients who were not on antiretroviral therapy at TB
diagnosis (68%) had significantly higher Aspergillus-spe-
cific IgG titers (P = 0.03) using Immulite, and 45% (14/
31) of them had CD4 T-cell counts less than 200 cells/
μl. Increased level of immunosuppression could still be
the contributing factor to this increased susceptibility to
the opportunistic fungal infection. There was no signifi-
cant difference in the Immulite Aspergillus-specific IgG
antibody levels (P = 0.66) between baseline and end of
TB treatment.
We observed a discrepancy in the Aspergillus-specific
IgG antibody levels between the ImmunoCAP and
Immulite. Previous studies comparing the ImmunoCAP
and Immulite have shown that the values for both tests
are highly correlated with antibody levels measured by
Immulite having a mean of 3 times higher than when
measured by ImmunoCAP. However, this correlation is
lost at high ImmunoCAP values [15]. This ratio may
change based on the specific antibody in question. In
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our current study, this ratio was approximately 1.6 on
average.
About 10% (9/93) of the participants had evidence of
Aspergillus sensitization at the end of TB treatment. This
was an expected outcome in this population since persist-
ence of pulmonary cavities after successful pulmonary TB
treatment is very common [16] and these cavities are
thought to harbour mould spores leading to fungal colon-
isation. Besides, ABPA can be misdiagnosed as pulmonary
TB, with some similar clinical features [10, 17]. However,
ABPA is rarely described outside chronic obstructive pul-
monary disease (COPD), asthma and cystic fibrosis. There
was no record of these three conditions in our partici-
pants, and therefore we argue that Aspergillus sensitisation
is the explanation for these high IgE results, which could
represent a strong T-helper 2 (Th2) response. The associ-
ation between ABPA and pulmonary TB has been weakly
described before mainly in case reports [18–20].
In a recent review, CPA in Uganda was estimated to
affect up to 22% of TB patients with cavities and 4% in
those without cavities [3]. However, in the current popula-
tion, pulmonary infiltrates were the most common chest x-
ray abnormality both at baseline (91%) and week 24 (41%).
Only 5% of our participants had pulmonary cavities on
chest x-ray at week 24. This did not change much from the
6% cavities registered at baseline. All the five patients with
cavities at week 24 had a good treatment outcome (cured)
but 3/5 had been diagnosed with smear negative TB at
baseline. This result supports previous work indicating per-
sistence of pulmonary cavities after successful pulmonary
TB treatment [16].
At week 24, 95% (95/100) of the chest x-rays showed
marked improvement from the baseline chest x-rays and
only 52% (52/100) were abnormal. Using ImmunoCAP,
all patients with normal and abnormal chest x-rays at
week 24 were negative for Aspergillus-specific IgG
(range: <2 to 9). However, using Immulite, there were
five positives among those with normal chest x-ray (me-
dian 7 [IQR: 5.9, 9.2]) and three positives among those
with abnormal chest x-rays (median 7.6 [IQR: 6.3, 10.3]).
We were unable to do computed tomography (CT)
scans of the chest, which might have provided better
definition of any residual abnormalities.
Total serum IgE is a test for general allergic disease
and parasitic infections. It is commonly used together
with fungal-allergy diagnostics. Using a cut-off of 170 IU/
ml for total serum IgE antibodies, 71% of participants
had evidence of allergic disease. This reduced to 58%
(49/85) at the end of TB treatment. Of these 49 partici-
pants with elevated total serum IgE antibodies at the end
of TB treatment, 12% (6/49) had elevated Aspergillus-
specific IgE antibody titers in the range of 0.41 to 2.4,
and Aspergillus-specific IgG antibody titers in the range
of 6.7 to 55.2.
The implication of the raised total serum IgE levels in
this population was not obvious. However, there is
evidence that total serum IgE levels tend to be more ele-
vated in non-asthmatic Africans than asthmatic Africans
[21]. Most scholars attribute this paradox to parasitic in-
festations in the African population [21, 22]. This paradox
therefore calls for the need to re-evaluate the role of total
serum IgE levels in asthma in areas with a high gut para-
site prevalence. Recent evidence from genotyping ancestry
informative markers indicated that African ancestry is a
risk factor for elevated total serum IgE levels in African
admixed population [23]. Intestinal helminths are also
known to raise total serum IgE levels in HIV patients even
without a fully functional CD4 T-cell repertoire [24–26].
Raising the cut-off for total serum IgE to 1000 IU/mL
reduced the positivity rate to more than 50%. Only 18 par-
ticipants had total serum IgE greater than 1000 IU/mL at
the end of TB treatment. Of these, 28% (5/18) had ele-
vated Aspergillus-specific IgE antibody titers in the range
of 0.41 to 2.4, and only two of these (2/5) had elevated As-
pergillus-specific IgG antibody titers (Immulite). Long
term coughing for more than three weeks at baseline was
also significantly related to increased total serum IgE titers
(P = 0.02). It is possible that some participants had both
TB and some form of allergy at baseline; which would ex-
plain the prolonged cough durations.
53% (51/97) of the patients had negative sputum smears.
Smear-negative tuberculosis was registered in 13 to 21% of
our participants at baseline. Among smear negative pa-
tients (n = 51), there were 16 positive genexperts, 20 posi-
tive MGIT and 13 positive LJ cultures. Seven patients were
negative for all the TB diagnostics (i.e. smear, genexpert,
MGIT, LJ) but with abnormal chest x-rays. These seven
patients were negative for Aspergillus IgG antibodies with
very low titers at both baseline and week 24. CPA associ-
ated with TB constitutes a significant unrecognized public
health problem, which is probably being incorrectly identi-
fied as ‘smear-negative tuberculosis’ especially in Africa.
Based on data from India, reduced pulmonary function
is associated with Aspergillus sensitisation, which unfortu-
nately we were unable to measure. Post-tuberculous se-
quelae include CPA, bronchiectasis [10] and to this we
add Aspergillus sensitisation. Reduced pulmonary function
persists in patients cured of TB [27], and Aspergillus sensi-
tisation could be one of the explanations, through poorly
understood mechanisms. The prevalence of pulmonary
Aspergillosis in HIV patients is underestimated in Africa
because of difficulty in accurate diagnosis. We have only
had a few epidemiological studies in Uganda [4, 6, 8].
However, in collaboration with The Global Action Fund
for Fungal Infections (GAFFI) and the University of Man-
chester, efforts are being put in place to train more my-
cologist and build laboratory capacity in Uganda. We
hope that this might solve the problem in the near future.
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Study limitations
The major limitation to the study was that we failed to
access control samples for comparison of these antibody
titers. This would possibly give more useful information.
So we agreed to move on without the controls since the
primary goal of this study was not to define diagnostic
cut-offs for assays that might subsequently be used in a
prevalence study in Uganda. Due to the limited pub-
lished data on fungal disease epidemiology in sub-
Saharan Africa, we found a major challenge in defining
which diagnostic cut-offs to use for Aspergillus-specific
IgG antibodies in both ImmunoCAP and Immulite. Pre-
viously published cut-offs range in 10 to 50 mg/l in simi-
lar populations. We were unable to do computed
tomography (CT) scans of the chest, which might have
provided better definition of any residual abnormalities.
Similarly, we did not add other tests like culture since
we used stored serum samples. Intestinal helminths are
known to raise total serum IgE levels in HIV patients
even without a fully functional CD4 T-cell repertoire
[24–26]. So the implication of the raised total serum IgE
levels in this population was not obvious. We observed a
discrepancy in the Aspergillus-specific IgG antibody
levels between the ImmunoCAP and Immulite similar to
what has been described before [15]. Cavities are known
to be the major predisposing factor to CPA in TB. How-
ever, in our population, cavities were seen in only 5% of
the participants.
Conclusion
In conclusion, Aspergillus-specific antibody levels were
significantly raised in patients being managed for pulmon-
ary tuberculosis. This colonization and/or sensitization by
Aspergillus antigens may complicate disease progression
and treatment outcomes among TB patients. Detection of
Aspergillus antibodies is an indispensable tool in the diag-
nosis and management of the patients with pulmonary as-
pergillosis. However, the detection of Aspergillus-specific
antibodies does not imply that the patient has an active
fungal disease; further diagnostic tests would be needed to
ascertain the presence of pulmonary aspergillosis. More
epidemiological studies are needed to explore and expand
the utility of Aspergillus antibody testing in resource lim-
ited setting.
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